- Demonstrates protection against major cardiovascular events, myocardial infarction and stroke to a significant extent as compared to monotherapy!
- Addition of clopidogrel to aspirin therapy demonstrated a significant decrease in the risk of major vascular events such as stroke
- Demonstrates a significant decrease in the rate of recurrent cardiovascular events in patients after percutaneous coronary intervention
- More effective in venous graft patency than aspirin alone in patients after coronary artery bypass grafting (CABG)